FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
Open Access
- 19 October 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 112 (1) , 314-322
Abstract
FMS‐like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis. However, the oncogenic role of FLT3 amplification in patients with metastatic colorectal cancer (mCRC) remains unclear. Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications. Tumor tissue samples from 2329 patients were sequenced using NGS in the Nationwide Cancer Genome Screening Project in Japan. The effects of clinicopathological features, co‐altered genes, prognosis, and efficacy of regorafenib were investigated. Between April 2015 and June 2018, 85 patients with mCRC with FLT3 amplification were observed. There were no differences in baseline characteristics between patients with or without FLT3 amplification. The frequency of RAS or other gene co‐alterations was inversely correlated with the copy number status. Median survival time in patients with FLT3 amplification was significantly shorter compared with those with non‐FLT3 amplification. Further investigations of FLT3 amplification as a potential treatment target in mCRC are warranted.Keywords
This publication has 23 references indexed in Scilit:
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- METExpression and Amplification in Patients with Localized Gastric CancerCancer Epidemiology, Biomarkers & Prevention, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human CancerCancer Research, 2010
- Deregulation of Signaling Pathways in Acute Myeloid LeukemiaSeminars in Oncology, 2008
- Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growthLeukemia, 2005
- Inhibition of FLT3 in MLLCancer Cell, 2003
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002